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Introduction:  Chronic  lymphocytic  leukemia 
(CLL)  is  the  most  common  hematologic 
malignancy in adults with an incidence rate of 4.2 
per  100,000  per  year.  CLL  frequently  takes  an 
indolent  course,  with  some  patients  not  requiring 
treatment for  years,  yet  is  incurable  by  currently 
available  chemo- and  immuno
modalities.  Despite  high  initial  response  rates, 
particularly to purine analogues, patients invariably 
relapse  and  subsequently  develop  resistance  to 
therapy.  The  traditional “watchful  waiting” 
approach  to  CLL  is  being  challenged  by  data 
showing that  treatments used  early  in  the  disease 
course  impact  long-term  overall  and  progression
free  survivals.
1-2 The  only  curative  treatment  for 
CLL  currently,  is  allogeneic  hematopoeietic  cell 
transplantation (alloHCT). 
In  contrast  to  autologous  transplant, 
myeloablative alloHCT for CLL patients generates 
durable  remissions  with  promising  survival 
plateaus;  however,  significant  transplant  related 
mortality  (TRM)  is  also  observed  (25
Rather than conditioning intensity, the graft
leukemia (GVL) effects appears to be the primary 
mechanism  behind  long-term  remission  in  this 
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Chronic  lymphocytic  leukemia 
(CLL)  is  the  most  common  hematologic 
malignancy in adults with an incidence rate of 4.2 
per  100,000  per  year.  CLL  frequently  takes  an 
indolent  course,  with  some  patients  not  requiring 
for  years,  yet  is  incurable  by  currently 
and  immuno-therapeutic 
modalities.  Despite  high  initial  response  rates, 
particularly to purine analogues, patients invariably 
relapse  and  subsequently  develop  resistance  to 
“watchful  waiting” 
approach  to  CLL  is  being  challenged  by  data 
showing that  treatments  used  early in  the  disease 
term  overall  and  progression-
The  only  curative  treatment  for 
CLL  currently,  is  allogeneic  hematopoeietic  cell 
In  contrast  to  autologous  transplant, 
myeloablative alloHCT for CLL patients generates 
durable  remissions  with  promising  survival 
,  significant  transplant  related 
mortality  (TRM)  is  also  observed  (25-50%).
3-4
Rather than conditioning intensity, the graft-versus-
leukemia (GVL) effects appears to be the primary 
term  remission  in  this 
patient population,
5-6 with some patients achieving 
CR  after  many  months  delay.
supporting  the  role  of  GVL  is  based  on  studies 
showing decreased risk of relapse in patients with 
chronic  GVHD, increased  risk  of  relapse with  T
cell  depletion,  remission  generated  by  donor 
lymphocyte infusion, as well as gradual elimination 
of minimal residual disease.
4,6-8
As the average age of CLL patients at diagno
is  72  years,  reduced  intensity  conditioning  (RIC) 
regimens are frequently necessary to decrease TRM 
and increase the availability of alloHCT for CLL
11 Due to this age skew, combined with the fact that 
GVL dominates the curative process, the majority
of  data on alloHCT for CLL has been  performed 
using reduced intensity regimens. Despite the lack 
of  head-to-head  comparisons  between  RIC  and 
myeloablative regimens, RIC has become standard 
in the field 
The selection of CLL patients for transplant is 
generally based on the European Group for Blood 
and  Marrow  Transplantation  (EBMT)  2007 
guidelines.
12 According  to  the  EBMT  CLL 
transplant consensus one of several criteria must be 
fulfilled for the prognostic risk to justify alloHCT. 
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with some patients achieving 
CR  after  many  months  delay.
4 The  evidence 
supporting  the  role  of  GVL  is  based  on  studies 
risk of relapse in patients with 
chronic  GVHD, increased  risk  of  relapse  with  T-
cell  depletion,  remission  generated  by  donor 
lymphocyte infusion, as well as gradual elimination 
As the average age of CLL patients at diagnosis 
is  72  years,  reduced  intensity  conditioning  (RIC) 
regimens are frequently necessary to decrease TRM 
and increase the availability of alloHCT for CLL.
9-
Due to this age skew, combined with the fact that 
GVL dominates the curative process, the majority
of  data on alloHCT for CLL  has been performed 
using reduced intensity regimens. Despite the lack 
head  comparisons  between  RIC  and 
myeloablative regimens, RIC has become standard 
The selection of CLL patients for transplant is 
rally based on the European Group for Blood 
and  Marrow  Transplantation  (EBMT)  2007 
According  to  the  EBMT  CLL 
transplant consensus one of several criteria must be 
fulfilled for the prognostic risk to justify alloHCT. Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
The  first  category  of  poor-risk  criteria  involves 
disease that is refractory to purine analogues; this 
includes primary refractory disease and recurrence 
within  short  intervals  following  initial  treatment 
with  purine  analogue  combination  therapy.  The 
highest-risk  category  includes  patients  with 
del(17p13) or other TP53 gene mutations. 
In  the  absence  of  multi-center  randomized 
prospective studies, the biggest challenges in CLL 
alloHCT therapy include selection of patients and 
timing of transplant during the disease course. To 
illustrate our approach to alloHCT for CLL patients, 
several case scenarios are presented, each followed 
by a discussion of the therapeutic implications. 
Case Discussions
Patient  1:  Very  high-risk  features  del(17p13). A 
45-year-old man presented with B-cell CLL, stage I 
Rai. His white blood cell count at presentation was 
120  x  10
9/L  with  95%  lymphocytosis,  bulky 
cervical  lymphadenopathy  and  constitutional 
symptoms of fatigue and night sweats. Cytogenetic 
analysis  of  the  bone  marrow  using  FISH  studies 
showed  del(17p13).  The  patient  was  treated  with 
standard  first-line  therapy,  fludarabine /
cyclophosphamide / rituximab (FCR), and achieved 
a complete clinical response with normalization of 
peripheral blood count and lymph node size. He had 
an  HLA-matched  sibling.  Based  on  the  EBMT 
consensus,  alloHCT  would  be  recommended  for 
such a patient.
As  multiple  prognostic  factors  for  CLL  are 
being investigated, determining which are the most 
useful  for  assessing  candidacy  for  alloHCT  has 
been  challenging.  The  four  molecular  biological 
features that have the best track records for use as 
markers  of  aggressive  disease  and  clinical 
prognostic  parameters  are:  recurrent  cytogenetic 
abnormalities  as  identified  by  FISH  testing,
8,13-14
immunoglobulin  variable  heavy-chain  (IGVH) 
mutational  status,
15-16 p53  gene  deletion,
17-18 ZAP 
70 expression,
19-20 and CD38 protein expression.
16
Cytogenetic abnormalities as assessed by FISH 
are a widely-applied prognostic tool. In an analysis 
by  Dohner  et  al.,
13 patients  with  deletions  in 
chromosome  band  17p13  had  a  median  survival 
from  diagnosis  of  2-3  years  as  compared  to  6-7 
years for those with deletions in 11q22, and 9 years 
for those with a normal karyotype. In addition to 
their  ability  to predict treatment-free  survival and 
OS, some biomarkers are also useful for predicting 
response  to  specific  therapeutic  agents.  The 
presence of del(17p) and/or abnormal p53 function 
have  consistently  been  shown  to  identify  CLL 
patients  whose  responses  to  purine  nucleoside 
analogs and alkylating agents are short-lived.
13-14,17-
18 Patients with 17p deletions experience treatment-
free intervals of only 9 months and PFS intervals of 
11 months after fludarabine based chemotherapy.
13-
14 The molecular basis for this clinical observation 
is  disruption  of  p53-dependent  apoptosis, 
responsible  for  the  anti-leukemic  effect  of  purine 
analogs  and  alkylating  agents,  in  patients  with 
del(17p13).
The weight of evidence does not convincingly 
demonstrate  that  IGHV  mutational  status  predicts 
progression-free  survival  after  transplant,  with 
studies by Byrd et al.
17 and Grever et al.
14 obtaining 
conflicting results. The ability of ZAP 70 and CD38 
expression  to  predict  response  to  treatment  and 
PFS/PS after treatment is even less clear.
16,19-21
Multiple  studies  demonstrate  that  allogeneic 
transplant can overcome the detrimental effects of 
negative indicators such as 17p and 11q deletion on 
prognosis
5-6,22 and  City  of  Hope  experience  also 
confirms  this  observation.  This  leveling  of  the 
playing field is particularly important, as no other 
options apart from clinical trials are  available for
these patients after they fail standard chemotherapy 
regimens. 
Appropriate  patients  with  del(17p13)  are 
candidates for allogeneic stem cell transplant early 
in the course of the disease – 1
st or 2
nd remission, 
given their high risk of non response for first-line 
therapy and/or  short  duration of  response.  In  this 
regard it is reasonable to initiate a donor search at 
the  time  first-line  therapy  is  initiated  for  patients 
with a 17p13 deletion. 
Patient  2:  Poor-risk  features  (progression 
<24month). A 62 year old woman was diagnosed 
with  B-cell  CLL  manifested  as  peripheral 
lymphocytosis  only.  After  3  years  of  a  watchful 
waiting approach, treatment was initiated based on 
peripheral  lymphocytosis  and  constitutional 
symptoms. FISH cytogenetic testing was performed 
on  peripheral  blood  and  no  17p  or  11q 
abnormalities were identified. She was treated with 
FCR as  standard first-line treatment and achieved 
clinical remission with normalization of peripheral 
lymphocytosis  and  resolution  of  B  symptoms. 
Within  21  months  she  progressed,  developing 
cervical  and  axillary  lymphadenopathy  and 
recurrent  lymphocytosis,  and  was  subsequently 
treated  with  bendamustin  and  rituxamab.  The 
patient  was  only  able  to  tolerate  an  abbreviated 
number of  treatment  courses due  to  pancytopenia 
and  achieved  a  partial  response.  The  FISH 
cytogenetic  testing  was  repeated  prior  to  second-
line treatment and showed a new clone with an 11q Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
deletion. The patient had no HLA-matched sibling 
but a 10/10 matched unrelated donor was identified 
at that time.
We recommend  repeat  testing  for  high-risk 
features at the time of each relapse or progression 
event  due  to  the  evolving biology  of  this  disease 
and  the  acquired  nature  of  these  mutations.  New 
cytogenetic  abnormalities  are  acquired  during 
follow-up in  more  that  25%  of  patients  over  a  5 
year  interval
23 and  are  associated  with  short 
survival. If a patient acquires poor genetic features 
during  the  course  of  the  disease  or  progresses 
within 24 months after initial therapy, the indication 
for  alloHCT  becomes  more  relevant  compared  to 
the  standard  choice  of  second  and  third  line 
treatment. 
This  patient’s  2- month  progression  in 
combination  with  the  acquired  cytogenetic 
abnormality  made  her  a  candidate  for  allo  HCT. 
The  use  of  reduced  intensity  conditioning  has 
become  standard  for  patients  with  CLL  and 
decreases transplant-associated toxicities, especially 
for  older  patients.  The  effectiveness  of  reduced-
intensity HCT for the treatment of CLL has been 
reported in the literature since 2003. Sorror et al. 
report  that  64  patients  treated  with  a  non-
myeloablative protocol using low dose TBI have a 
2-year OS of 60%, DFS of 52% with a TRM 22% 
and significant GVHD.
11 Using a non-myeloabative 
FCR  conditioning  regimen  employing  early 
tapering  of  immunosupression  and  use  of  rituxan 
and  DLI  for  immunomodulation,  Khouri  et  al.
estimate a 4-year OS of 48% and a current PFS of 
44%.
5 In  46  patients  treated  using  a  non-
myeloablative regimen of fludarabine and low dose 
busulfan, Brown et al. report a 2-year OS of 54% 
and  PFS  of  34%  with  17%  TRM  and  a  2-year 
cumulative incidence of relapse of 48%.
24
Our own data from COH were presented at the 
Rome  Congress,  “New  drugs  and  hematopoietic 
stem  cell  transplantation  in  oncohematological 
diseases of the elderly” as an oral presentation in 
November of 2009.
25 We presented an analysis of 
data from 27 CLL patients treated using alloHCT 
with  fludarabine-based  reduced  intensity 
conditioning demonstrate overall survivals (OS) and 
progression-free  survivals  (PFS)  of  80.0%  and 
72.8% at 1 year and 64.0% and 62.4% at 2 years. 
The  relapse/progression  rate  was  15.4%  and  the 
non-relapse  mortality  (NRM)  was  24.7%,  at  2 
years.  The  best  response  post  transplant  was 
complete remission in 19 patients (70.4%), partial 
response  in  4  (14.8%)  and  stable  disease  in  one 
(3.7%).
25
For patients such as this man, who do not have 
HLA-matched siblings, use of a matched unrelated 
donor  (MUD)  is  a  valuable  option.  Based  on 
extensive registry data from the EBMT,
26 the Center 
for  International  Blood  and  Marrow  Transplant 
Research (CIBMTR)
27 and multivariate analysis of 
data effecting OS after RIC and myeloablative HCT 
in patients with CLL, there is no evidence of the 
inferiority of a well-matched MUD (10/10) versus 
HLA-matched sibling donors. Therefore, for older 
CLL patients with good performance status MUD 
transplant  with  reduced  intensity  conditioning 
would be a reasonable choice with curative intent.
Patient  3:  Disease  refractory  to  fludarabine and 
alemtuzumab. A 55-year-old male patient with B-
cell  CLL,  diagnosed  initially  at  stage  I  Rai, 
manifested  with  mild  lymphocytosis  and  small 
peripheral  lymphadenopathy. The  patient  was 
observed  for  5  years  and  eventually  developed 
bulky lymphadenopahy, and was treated with FCR, 
resulting in a complete response. After 3 years, he 
developed  recurrent  lymphocytosis  and 
lymphadenopathy,  and  was  re-treated  with 
fludarabine/rituximab  with  no  response  and 
significant cytopenia. He was subsequently treated 
with  alemtuzumab, attaining  partial response. The 
patient  progressed  again  within  1  year,  and  was 
treated with a bendamustin and rituxan combination 
with no response. The patient had an HLA-matched 
sibling.
Unfortunately,  this  is  an  all-too-familiar 
scenario  with  CLL  patients  going  to  transplant. 
They  have  often  been  heavily  pre-treated  and 
eventually  become  chemo-resistant.  Ruling  out 
transformation  into  more  aggressive  types  of 
lymphoma,  known  as  Richter’s  syndrome,  is  an 
important step in the assessment of CLL patients, 
particularly  when  confronted  with  progressively 
refractory  behavior.  Richter’s  transformation 
diagnosed in a CLL patient at any time during the 
disease  course  is  by  itself  an  indication  for 
allogeneic  stem  cell  transplant  as  these  patients 
have a dismal prognosis.
28
At  COH  we  have  found  that  chemotherapy-
refractory  disease  is  associated  with  inferior 
progression-free  survival  in  our  RIC  allo  HCT 
patients, an association supported by Sorror et al.
29
in a study with a large percentage of chemoresistant 
patients.  Bulky  lymphadenopathy  at  the  time  of 
transplant is also associated with poor progression-
free  survival  in  our  patient  population.
25 It  is 
possible that chemo-resistance could be a marker of 
aggressive disease that progresses too rapidly to be 
controlled by even an active immune response of Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
GVL  rather  that  actual  predictor  of  intrinsic 
resistance  to  GVL  activity.  Therefore,  would 
cytoreduction  before  transplantation  improve 
outcome? 
The  use  of  non-myeloablative  conditioning 
could possibly result in insufficient cytoreduction, 
which  would  interfere  with  engraftment  and  the 
anti-leukemia  effect  by  not  allowing  time  for 
development  of  GVL.  More  aggressive 
cytoreduction  approaches  may  be  necessary  to 
enhance  the  GVL  effect.  Aggressive  debulking 
prior  to  transplant,  the  use  of  reduced  intensity 
regimens  (such  as  fludarabine/melphalan)  rather 
than purely non-ablative preparative regimens (such 
as FCR or single-dose TBI-based), and additional
immunotherapy with monoclonal antibodies during 
or  following  transplant,  are  potential  ways  to 
improve  the  efficacy  of  transplant  with  reduced 
intensity conditioning. 
Aggressive  debulking  prior  to  transplant  is 
advocated by MD Anderson with a chemotherapy 
regimen  such  as 
oxaliplatin/fludarabine/cytarabine/rituximab 
(OFAR). A total of 70% of the patients treated with 
this  approach  achieve  prolonged  survival  after 
subsequent  HCT.
30 Addition  of  the  monoclonal 
antibody alemtuzumab can decrease GVHD while 
contributing to disease control, but this delays post-
HCT immune reconstitution, increases  the  risk  of 
infectious  complications  and  impairs  the  GVL 
effect. Delgado et al. report on 41 patients treated 
with  fludarabine,  melphalan  and  alemtuzumab 
demonstrating  an  OS  at  2  years  of  51%  and  a 
relapse risk of 29% at 2 years; TRM is also 29% 
due  to  a  high  incidence  of  fungal  and  vial 
infections.
31
The  addition  of  high  dose  rituximab  to  pre-
transplant conditioning has been employed
10,32 and 
may  serve several purposes. The  most obvious  is 
bone marrow  cytoreduction  to  allow time  for  the 
GVL effect. Inclusion of rituximab as part of the 
preparative  regimen  would  act  to  deplete  both 
recipient and donor derived B-cells. There is also 
evidence  that  B-cells  functioning  as  antigen-
presenting cells may have an important role in the 
pathogenesis of GVHD,
33 so rituximab could also 
lower the incidence of GVHD via their elimination. 
It is preferable to refer patients for  transplant 
before  they  become  truly  refractory  to 
chemotherapy,  as  patients  with  transformed  or 
bulky disease at the time of transplant have inferior 
outcomes.  In  addition,  protracted  treatment  with 
nucleoside analogs and monoclonal antibodies, both 
T- and  B-cell  depleting,  can  contribute  to 
immunosuppression  and  increase  the  risk  of 
opportunistic infections during transplant or salvage 
chemotherapy. However, for a patient such as this, 
debulking could be attempted with a regimen such 
as  oxaliplatin/fludarabine/cytarabine/rituximab 
(OFAR)  or  salvage  regimens  employed  for 
agressive  B-cell  lymphomas.  Response to  salvage 
treatment prior  to transplant would correlate with 
improved  transplant  outcome.  In  terms  of 
conditioning  regimen,  the  choice  of  reduced 
intensity  but  still  cytoreductive  conditioning  with 
addition of anti CD20 monoclonal antibody rather 
than  purely  non  myelobalative would  be  optimal. 
The  transplantation-related  risk,  including  major 
infectious episodes needs to be emphasized during 
and after transplantation.
Patient 4: Delayed achievement of CR assessed by 
MRD. A 65 year-old patient was initially diagnosed 
with  peripheral  lymphocytosis.  After  2  years  of 
observation  he  progressed  with  peripheral 
lymphocytosis  and  was  treated  with  FCR.  No 
cytogenetic abnormalities were found on peripheral 
blood FISH studies. He remained in remission for 3 
years  and  eventually  developed  progression  of 
lymphocytosis  with  no  significant  lymph  node 
involvement  and  was  treated  with  alemtuzumab, 
achieving  partial  resposne.  After  one  year  he 
developed  pancytopenia  with  70%  leukemia 
involvement of the bone marrow. He was unable to 
tolerate bendamustin/rituxan due to cytopenia. The 
patient was found to have an HLA-matched sibling 
and  underwent  non  myeloablative  alloHCT  with 
fludarabine  /  cyclophosphamide  /  rituximab 
conditioning with gross bone marrow involvement 
at  the  time  of  transplant.  He  tolerated  the 
conditioning well,  and achieved 90%  engraftment 
by STR analysis but showed evidence of residual 
disease by positive MRD testing at day 100. He was 
treated pre-emptively with rituximab and achieved 
MRD negativity at 6 months post transplant.
The  quality  of  remission  represented  by 
cytogenetic, molecular and minimal residual disease 
(MRD) assays is being increasingly recognized as 
an important prognostic factor in many hematologic 
malignancies.  As  the  goal  in  CLL  treatment  has 
moved  from  palliative  care  toward  durable 
remission,  MRD  monitoring  has  become  a 
significant  assessment  tool  in  the  management  of 
CLL. MRD eradication is an important target in the 
treatment  of  CLL  because  MRD  negativity  is 
clearly correlated with improved outcome.
4-6,34 With 
standard  chemotherapy  regimens  disease 
progression is inevitable in patients who are MRD-
positive, whereas MRD-negative patients are able to 
attain durable remissions.
35Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Studies  of  unmutated  IgVH  MRD  kinetics 
following  autologous  and allogeneic  transplant
6,36
showed that the presence of detectable unmutated 
IgVH MRD early after transplant does not have an 
impact on allograft outcome in CLL. Ritgen et al.
report that MRD becomes undetectable beyond day 
100 in 78% patients after alloHCT and correlates 
with  long-term  CR  and  MR.  On  the  other  hand, 
negative MRD states achieved after autoHCT with 
similar  conditioning  are  not  durable  and  the 
presence  of  detectable  MRD  post  autoHCT  is 
associated  with  high  risk  for  relapse.  These 
observations  suggest  that  the  GVL  effect  is  the 
driving  force  behind  clearance  of  MRD  after 
transplant.
Patients with a high tumor burden or atypical 
morphology (Richters transformation) are at highest 
risk  for  early  progression  after  alloHCT  and  are 
good  candidates  for  MRD  testing  after  alloHCT. 
The use of MRD allows post-transplant detection of 
preclinical relapse, enabling the early initiation of 
adoptive  immunotherapy  including  prompt 
withdrawal  of  immunosupression,  donor 
lymphocyte  infusion  (DLI),  monoclonal  antibody 
infusion,  or  a  combination  of  immunotherapies. 
Khouri  et  al:  report  on  a  non-myeloabative  FCR 
conditioning regimen  employing  early  tapering  of 
immunosupression and use of rituxan and DLI for 
immunomodulation.
5 In this study, progression-free 
survival, prior to any immunomodulatory treatment 
was  30%  at  5  years,  but  when  including  the 
immunomodulatory  treatment  of  persistent  or 
progressive disease as part of the regimen, “current 
progression-free  survival”  attained  53%  at  five 
years. 
MRD  assessment  is  performed  using 
standardized  protocols  of  either  4-color  flow 
cytometry  or  allele-specific  oligonucleotide  PCR 
(with a  sensitivity  of  one  CLL  cell  per  10,000 
leukocytes)  and  can  be  performed  on  peripheral 
blood  samples.
35 MRD  testing  is  currently 
employed primarily for patients treated on clinical 
trials,  but  as  future  treatment  and  assay 
development progresses it may became a useful tool 
in monitoring of treatment efficacy.
Conclusions: The  advent  of  novel  agents  with 
activity  in  CLL,  including  antibodies  such  as 
alemtuzumab,
37 anti-CD20  ofatumumab,  and  anti-
CD23  lumiliximab;  BCL2  inhibitors  such  as 
oblimersen and ABT263; immunomodulatory drug 
lenalidimide; and cyclin-dependent kinase inhibitor 
flavopiridol,  may  change  the  paradigms  in  CLL 
therapy.  Several  of  these  agents  show  strong 
indications of activity in CLL, although some are 
still in clinical trials. Thus far, the fact remains that 
for poor-risk CLL,  alloHCT is the only treatment 
with  the  potential  of  providing  long-term  disease 
control.  Future  combinations  with  emerging  low-
toxicity therapies may further enhance the curative 
potential  of  allogeniec  hematopoietic cell 
transplant.  New  drugs can  also potentially  enable 
refractory patients to attain response as a bridge to 
more effective stem cell transplantation.
It is important to emphasize that patients with 
refractory disease should be treated within clinical 
trials whenever possible. Although there is no doubt 
that alloHCT can improve the prognosis of selected 
poor-risk  patients,  its  place  in  the  treatment 
algorithm  for  the  general  population  of  CLL 
patients  is  still  unclear.  This  question  can  be 
properly  addressed  only  by  prospective  trials 
comparing  alloHCT  with  non-transplant  chemo-
immunotherapy strategies. The German CLL Study 
Group  is  currently  proposing  a  trial  aiming  at 
validation  of  the  EBMT  criteria  in  patients  with 
high-risk and very high-risk CLL. This trial would 
give further guidance regarding when and how to 
use alloHCT in poor-risk CLL. Until then, the data 
from retrospective and prospective studies provided 
by  the  cooperative  groups  and  large  transplant 
centers,  including  City  of  Hope,  remain  valuable 
sources of information. 
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